Company Filing History:
Years Active: 2021
Title: Ronald R. Hiebsch: Innovator in Cancer Therapeutics
Introduction
Ronald R. Hiebsch is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of cancer therapeutics through his innovative work on anti-SIRPα monoclonal antibodies. His research focuses on developing distinct functional profiles for these antibodies, which are crucial in the prevention and treatment of various cancers.
Latest Patents
Hiebsch holds a patent for "Therapeutic SIRP-α antibodies." This patent includes anti-SIRPα monoclonal antibodies, as well as multispecific SIRPα antibodies. These antibodies are designed with unique functional profiles and are intended for use as therapeutics in treating solid and hematological cancers. The patent also provides amino acid sequences of exemplary anti-SIRPα monoclonal antibodies, showcasing the depth of his research.
Career Highlights
Hiebsch is currently associated with Arch Oncology, Inc., where he continues to advance his research in cancer therapeutics. His work has the potential to significantly impact the treatment landscape for patients suffering from various forms of cancer.
Collaborations
He collaborates with talented individuals such as Robyn Puro and Benjamin J. Capoccia, who contribute to the innovative environment at Arch Oncology, Inc. Their combined expertise enhances the development of groundbreaking therapeutic solutions.
Conclusion
Ronald R. Hiebsch's contributions to the field of cancer therapeutics through his patent on anti-SIRPα monoclonal antibodies exemplify his commitment to innovation in medicine. His work continues to pave the way for new treatment options for cancer patients.